No pet lover wants to hear this, but around 6 million dogs are diagnosed with cancer in the US every year. Cancer is, heartbreakingly, the main reason dogs die. But don’t despair: scientists are working on it.
A recent study has shed light on a potential breakthrough in the treatment of canine cancer. Researchers have discovered a correlation between certain types of bacteria in the gut microbiomes of dogs with cancer and their survival rates after immunotherapy treatment.
Similar to studies in humans, these findings suggest that specific gut microbiome signatures could serve as diagnostic or prognostic biomarkers for canine cancer patients undergoing immunotherapy.
A clinical trial conducted at the Bridge Animal Referral Center in the US enrolled fifty-one canine cancer patients to test a new cancer immunotherapy vaccine. This vaccine targets two proteins, EGFR and HER2, which are overexpressed in certain cancers, to help the immune system fight tumor growth.
Researchers analyzed rectal swabs from the dogs at Bridge and identified 11 types of bacteria that appeared to influence the success of the vaccine. Four of these bacteria were associated with longer survival times after treatment, while seven were linked to shorter survival.
These findings suggest that a dog’s gut bacteria play a crucial role in modulating immune responses, even against non-intestinal cancers like osteosarcoma or hemangiosarcoma.
While the study did not delve into the mechanisms by which these bacteria affect outcomes, researchers believe that manipulating the gut microbiome could enhance the efficacy of cancer treatments in dogs and potentially serve as a model for human treatments.
Natalia Shulzhenko, a researcher at Oregon State University, emphasizes the potential of using the gut microbiome as a tool for developing prognoses and manipulating cancer outcomes in dogs and potentially in humans as well.
Although the research is still in its early stages, the findings suggest that microbial treatments such as probiotics or fecal transplants could complement canine cancer vaccines in the future.
Shulzhenko envisions a future where analysis of a microbiome swab could predict a dog’s response to cancer treatment, enabling pet owners and veterinarians to make more informed decisions about care.
The study was published in Veterinary Oncology, marking a significant step forward in understanding the role of gut bacteria in canine cancer treatment.
